Skip to main content

Table 2 Tumor dose and administered activity results for the addition of 131 I-MIBG to 90 Y-DOTATOC

From: Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

Subject MIBG vs. pentetreotide image pattern for metastases Maximum activity (GBq)90Y-DOTA alone (over multiple cycles) Optimum percentage of max90Y-DOTA activity to be given when adding MIBG Activity (GBq) of131I-MIBG that can be added without exceeding limits (over multiple cycles) Tumor dose (cGy):90Y-DOTA given alone Tumor dose (cGy):90Y-DOTA + 131I-MIBG
1 Concordant 13.5 72 32.2 1,623 7,618
2 All tumors MIBG negative      
3 All tumors MIBG negative      
4 Discordant 11.1 88 29.8 3,317 11,119
5 All tumors MIBG negative      
6 Discordant 14.4 16 42.8 10,330 45,737
7 Discordant 19.8 100 0.0 14,068 14,068
8 Discordant 4.9 75 33.3 1,006 2,499
9 Concordant 7.2 76 45.0 729 2,829
10 All tumors MIBG negative      
Calculated using average dosimetry results from the literaturea N/A 10.7 85 36.4 4,685 14,555
  1. Total renal limit, 23 Gy; total marrow limit, 3 Gy. N/A, not applicable. aResults in this row were calculated using average dose values for the marrow, kidneys, and NETs from the literature.